Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Astrup, Preeyaporn Sarangarm, Allison Burnett (2018)
Fixed dose 4-factor prothrombin complex concentrate for the emergent reversal of warfarin: a retrospective analysisJournal of Thrombosis and Thrombolysis, 45
Rahat Abdoellakhan, I. Miah, N. Khorsand, K. Meijer, K. Jellema (2016)
Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective AnalysisNeurocritical Care, 26
R. Sarode, T. Milling, M. Refaai, A. Mangione, A. Schneider, B. Durn, J. Goldstein (2013)
Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding: A Randomized, Plasma-Controlled, Phase IIIb StudyCirculation, 128
Ruben Acosta, N. Abraham, V. Chandrasekhara, K. Chathadi, D. Early, M. Eloubeidi, John Evans, A. Faulx, D. Fisher, Lisa Fonkalsrud, J. Hwang, M. Khashab, J. Lightdale, V. Muthusamy, S. Pasha, J. Saltzman, A. Shaukat, A. Shergill, Amy Wang, B. Cash, J. DeWitt (2016)
The management of antithrombotic agents for patients undergoing GI endoscopy.Gastrointestinal endoscopy, 83 1
N. Khorsand, N. Veeger, R. Hest, P. Ypma, J. Heidt, K. Meijer (2012)
An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergenciesHaematologica, 97
(2018)
IL: Kankakee
(2016)
American Society for Gastrointestinal Endoscopy (ASGE) Standards of Practice
K. Smetana, R. Ziemba, Casey May, Michael Erdman, Edward Matre, G. Jones (2018)
Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleedingJournal of Thrombosis and Thrombolysis, 47
J. Frontera, John III, A. Rabinstein, I. Aisiku, A. Alexandrov, A. Cook, G. Zoppo, Monisha Kumar, E. Peerschke, M. Stiefel, J. Teitelbaum, K. Wartenberg, C. Zerfoss (2016)
Guideline for Reversal of Antithrombotics in Intracranial HemorrhageNeurocritical Care, 24
(2011)
Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis
A. Holbrook, S. Schulman, D. Witt, P. Vandvik, Jason Fish, M. Kovacs, P. Svensson, D. Veenstra, M. Crowther, G. Guyatt (2012)
Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest, 141 2 Suppl
G. Tomaselli, K. Mahaffey, A. Cuker, P. Dobesh, J. Doherty, J. Eikelboom, R. Florido, W. Hucker, R. Mehran, S. Messé, C. Pollack, Fatima Rodriguez, R. Sarode, D. Siegal, B. Wiggins (2017)
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.Journal of the American College of Cardiology, 70 24
C. Varga, Sultan Al-Touri, S. Papadoukakis, S. Caplan, S. Kahn, M. Blostein (2013)
The effectiveness and safety of fixed low‐dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin (CME)Transfusion, 53
G. Gulati, Megan Hevelow, Melissa George, E. Behling, J. Siegel (2011)
International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy.Archives of pathology & laboratory medicine, 135 4
J. Gorlin, S. Kinney, Mark Fung, A. Tinmouth (2017)
Prothrombin complex concentrate for emergent reversal of warfarin: an international survey of hospital protocolsVox Sanguinis, 112
L. Klein, Jessica Peters, J. Miner, J. Gorlin (2015)
Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal.The American journal of emergency medicine, 33 9
Sacha Sølbeck, S. Ostrowski, P. Johansson (2012)
A review of the clinical utility of INR to monitor and guide administration of prothrombin complex concentrate to orally anticoagulated patientsThrombosis Journal, 10
D. Witt, R. Nieuwlaat, N. Clark, J. Ansell, A. Holbrook, J. Skov, Nadine Shehab, J. Mock, Tarra Myers, F. Dentali, M. Crowther, A. Agarwal, Meha Bhatt, R. Khatib, J. Riva, Y. Zhang, G. Guyatt (2018)
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.Blood advances, 2 22
R. Scott, Brian Kersten, J. Basior, Megan Nadler (2018)
Evaluation of Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal in Patients with Intracranial Hemorrhage.The Journal of emergency medicine, 54 6
IntroductionDespite an increase in the use of fixed-dose protocols of 4-factor prothrombin complex concentrate (4F-PCC) for the reversal of vitamin K antagonists (VKAs), there remains a paucity of data in obese patients. In this study, we aimed to compare the proportion of patients attaining international normalized ratio (INR) goals using a weight-based dosing strategy versus a fixed-dose regimen of 4F-PCC.MethodsThis was a retrospective study conducted in patients 18 years of age or older, weighing ≥ 100 kg, who received either a weight-based dose or fixed dose of 4F-PCC (2000 units) for the reversal of VKA, and had a documented baseline and post-treatment INR. The primary outcome was the proportion of patients achieving an INR of < 2 for all indications of warfarin reversal, except in patients with intracranial hemorrhage, where the goal was an INR of < 1.5.ResultsA total of 44 patients met the inclusion criteria; 25 patients in the weight-based dosing group and 19 patients in the fixed-dose group. The median baseline INR was similar in both groups (weight-based dosing group 3.2 [interquartile range {IQR} 2.8–3.7] vs fixed-dose group 3.0 [IQR 2.7–4.9], p = 1). The median post-treatment INR was significantly lower in the weight-based dosing group compared to the fixed-dose group (1.3 [IQR 1.2–1.5] vs 1.6 [IQR 1.5–1.9], p < 0.01). However, there was no significant difference in the primary outcome between both groups (weight-based dosing strategy 84% vs fixed dose strategy 90%, p = 0.68).ConclusionOur findings suggest that a fixed-dose regimen of 2000 units in obese patients weighing ≥ 100 kg is adequate to achieve these INR goals.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Nov 5, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.